Cellectis Presents Preclinical APOC3 Editing Data for.HEAL-101
Cellectis presented preclinical data highlighting APOC3 editing and triglyceride reduction with.HEAL-101 at ESGCT 2026.
Related stories
Leonardo DRS Reports Higher Q3 Adjusted Earnings and Revenue, Raises 2026 Guidance
Leonardo DRS reported higher Q3 adjusted earnings and revenue and raised its 2026 guidance.
M impact | EQUITY | Oct 29, 2026, 12:16 PM UTC
CACI Wins Five-Year U.S. Army Task Order Valued at Up to $185 Million
CACI says the task order supports the Army's Program Manager Expeditionary Energy and Sustainment Systems. The company will develop and integrate expeditionary power capabilities.
M impact | EQUITY | Oct 29, 2026, 12:16 PM UTC
Beyond Air Schedules Quarterly Results Conference Call
Beyond Air scheduled a conference call to discuss quarterly financial results.
M impact | EQUITY | Oct 29, 2026, 12:16 PM UTC
Borr Drilling Confirms Three Bodies Located After Prospector 5 Incident
Borr Drilling said three bodies were located after the Prospector 5 incident offshore Gabon; two people remain unaccounted for. About 280 m³ of marine diesel was onboard, and mitig
M impact | EQUITY | Oct 29, 2026, 12:16 PM UTC
BioHarvest Sciences announces third-quarter results presentation
BioHarvest Sciences announced a presentation of its third-quarter results.
M impact | EQUITY | Oct 29, 2026, 12:16 PM UTC
Arab Phoenix Holdings Reports Q3 Loss of 102,187 Dinars
M impact | EQUITY | Oct 29, 2026, 12:15 PM UTC